The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
European Cardiology Review · 26.05.2026
DOI: 10.15420/ecr.2025.84 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 26.05.2026. Verfasst von Alex E Henney und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Metabolic Medicine, University of Liverpool Liverpool, UK. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The global prevalence of obesity has more than tripled since 1975, now affecting nearly one billion adults and over 170 million children and adolescents. In 2025, The Lancet Diabetes & Endocrinology Commission on Clinical Obesity redefined obesity as a chronic, multisystem disease characterised by excess adiposity leading to organ dysfunction, distinguishing between preclinical obesity (excess adiposity without end-organ injury) and clinical obesity (manifest metabolic or structural complications). This framework moves beyond reliance on BMI, acknowledging that ectopic fat deposition in the liver, muscle and viscera is a more accurate determinant of cardiometabolic and hepatic risk. Once considered a disease of affluence, obesity is now increasing most rapidly in rural and low- to middle-income countries, driven by urbanisation of lifestyle, reduced physical activity and the proliferation of ultra-processed foods. The result is a parallel escalation in non-communicable diseases, with obesity underpinning cardiovascular, metabolic, hepatic, renal, respiratory, oncological and psychological disorders, among others. Cardiovascular disease remains the leading cause of obesity-related mortality, while type 2 diabetes, metabolic dysfunction-associated steatotic liver disease and chronic kidney disease contribute substantially to morbidity. Economically, obesity accounted for 2.2% of global GDP in 2019 and is projected to exceed 3% by 2060. Emerging therapies, particularly glucagon-like peptide-1 (GLP-1) and dual GLP-1/glucose-dependent insulinotropic peptide receptor agonists, now achieve weight loss comparable to metabolic bariatric surgery while reducing cardiovascular, metabolic and hepatic complications, independent of weight loss. Future strategies must integrate precision medicine with equitable, scalable public health policies to address this escalating global epidemic and its societal costs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular and Metabolic Medicine, University of Liverpool Liverpool, UK.
- Metabolism and Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust Liverpool, Merseyside, UK.
ORCID-Profile: Alex E Henney, John Ph Wilding
Zitieren
APA
Henney, A. E., & Wilding, J. P. (2026). The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities. European Cardiology Review. https://doi.org/10.15420/ecr.2025.84
Vancouver
Henney AE, Wilding JP. The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities. European Cardiology Review. 2026. doi:10.15420/ecr.2025.84
BibTeX
@article{Henney2026,
author = {Henney, Alex E and Wilding, John Ph},
title = {The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities},
journal = {European Cardiology Review},
year = {2026},
doi = {10.15420/ecr.2025.84}
}
EUVIMED